Animal Pharm podcast #12: Could an IPO be the most viable option for Elanco?
With a decision on Elanco's future due in a week, Animal Pharm editor Joseph Harvey provides a recap of the company's situation and what can be expected over the next seven days.
The podcast below covers Elanco's financial performance from 1990 until now, the firm's R&D situation and the four potential scenarios that Eli Lilly could opt for next week.
The podcast also features the results of Animal Pharm's poll on the future of Elanco, which has been running over the past week. The poll is still active and the results mentioned in the podcast were accurate at the time of recording. The latest poll voting is displayed below.
Elanco's future will become a lot clearer on July 24, when Eli Lilly publishes its second-quarter results. Lilly has been conducting a strategic review of its animal health division over the past nine months.
What will the future hold for @Elanco? Lots of rumors have been circulating regarding an IPOs, acquisition, mergers etc... So let us know what you think and vote here #animalhealth — Joseph Harvey (@JHJournalist) July 10, 2018